Beam Therapeutics Inc.
- Open
- 28.82
- Day high
- 29.82
- Day low
- 28.41
- Prev close
- 29.32
- Volume
- 1.3M
- Mkt cap
- $3.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.8
- P/S
- 19.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$12.2M over the last 3 months (0 open-market buys, 8 sales)
- 🏛Institutions accumulating (13F)
Beam Therapeutics Inc. (BEAM) is a Healthcare company listed on NASDAQ. The stock is up 79% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 8 sales (SEC Form 4).
Beam Therapeutics Inc. (BEAM) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BEAM earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $-1.11 | $-1.18 | -6.3% | $490000 | -97.0% |
| May 7, 2026 | $-0.87 | $-0.91 | -4.6% | $32M | +189.1% |
| Feb 24, 2026 | $-1.13 | $-0.10 | +91.2% | $114M | +970.0% |
| Nov 4, 2025 | $-0.98 | $-1.10 | -12.2% | $10M | -26.6% |
| Feb 27, 2024 | $-1.01 | $1.73 | +271.3% | $316M | +1593.6% |
| Feb 28, 2023 | $-1.32 | $-0.54 | +59.1% | $20M | +57.6% |
| Feb 28, 2022 | $-1.02 | $-0.85 | +16.7% | $51M | +496.4% |
| Aug 10, 2021 | $-0.58 | $-0.95 | -63.8% | $6000 | +11.6% |
| Mar 15, 2021 | $-0.70 | $-0.72 | -2.9% | $6000 | — |
| Aug 12, 2020 | $-0.56 | $-0.69 | -23.2% | $6000 | +30.2% |
| Feb 7, 2020 | — | $-0.54 | — | $6000 | — |
| Jun 29, 2019 | — | $-0.51 | — | $6000 | — |
BEAM insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 29, 2026 | Simon Amyofficer: Chief Medical Officer | Sell | 16,667 | $25.74 |
| Jul 2, 2026 | Simon Amyofficer: Chief Medical Officer | Sell | 373 | $34.73 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Option | 18,663 | $0.67 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Sell | 23,100 | $34.26 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Sell | 13,421 | $35.13 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Option | 25,000 | $1.03 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Sell | 11,579 | $35.91 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Option | 6,337 | $1.03 |
| Jul 1, 2026 | Evans John M.director, officer: CEO | Sell | 1,900 | $34.84 |
| Jun 29, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sell | 251,488 | $35.26 |
| Jun 29, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sell | 33,372 | $35.12 |
| Jun 22, 2026 | Ciaramella Giuseppeofficer: President | Option | 6,505 | $0.67 |
| Jun 22, 2026 | Ciaramella Giuseppeofficer: President | Option | 29,000 | $1.03 |
| Jun 5, 2026 | MARAGANORE JOHNdirector | Grant | 19,676 | $29.55 |
| Jun 5, 2026 | Walsh Kathleen Edirector | Grant | 19,676 | $29.55 |
Source: BEAM SEC Form 4 filings, latest Jul 29, 2026. For informational purposes only — not investment advice.
See the full BEAM insider & 13F page →Beam Therapeutics Inc. company profile
Overview
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company founded in 2017 and based in Cambridge, Massachusetts. The company went public in February 2020 and has emerged as a leader in precision genetic medicine, specifically focusing on base editing technology to develop treatments for serious genetic diseases. Beam has built a comprehensive pipeline of experimental therapies targeting blood disorders, liver diseases, and other genetic conditions, with several programs advancing through clinical trials.
Business
Beam Therapeutics operates in the precision genetic medicine sector of biotechnology, developing therapies using a cutting-edge gene editing technology called base editing. Unlike traditional gene therapy approaches that cut DNA strands, base editing allows scientists to make precise, single-letter changes to DNA without creating double-strand breaks, potentially offering safer and more targeted genetic modifications. The company's pipeline is organized into three main therapeutic areas: 1. **Hematology Franchise (Blood Disorders)** - This represents the most advanced segment of Beam's portfolio. The flagship program BEAM-101 targets sickle cell disease and beta thalassemia, two inherited blood disorders caused by mutations in hemoglobin genes. BEAM-102 is a second-generation therapy also for sickle cell disease. The company has also developed BEAM-201, an allogeneic CAR-T cell therapy for treating a type of blood cancer called T-cell acute lymphoblastic leukemia. 2. **Liver Genetic Diseases** - This segment includes BEAM-301 for Glycogen Storage Disease Type Ia, a rare condition where the body cannot properly break down stored sugar, and BEAM-302 for alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver problems. These therapies are designed to correct the underlying genetic defects in liver cells. 3. **Other Genetic Disorders** - Beam is developing treatments for various other conditions including ocular (eye) diseases, muscle disorders, and central nervous system conditions, though these programs are in earlier stages of development. The company has also developed ESCAPE technology, an innovative approach that could potentially eliminate the need for chemotherapy conditioning in stem cell transplants by using engineered antibodies to create space in the bone marrow for edited cells.
Revenue model
Beam Therapeutics generates revenue through multiple channels, though the company is still in the clinical development stage and not yet profitable. The primary revenue sources include collaboration agreements and licensing deals with pharmaceutical partners such as Pfizer, Apellis Pharmaceuticals, and Verve Therapeutics. These partnerships typically involve upfront payments, milestone payments as programs advance through development, and potential royalties on future sales. The company's business model is built around developing proprietary base editing therapies through clinical trials, with the ultimate goal of bringing these treatments to market either independently or through partnerships. For the most advanced programs like BEAM-101, Beam may choose to commercialize independently in certain markets while partnering for global expansion. Several factors could significantly impact Beam's future profitability and margins. Positive clinical trial results, particularly for BEAM-101 in sickle cell disease, could dramatically increase the company's valuation and attract additional partnerships. The successful implementation of ESCAPE technology could expand the addressable patient population by eliminating the need for harsh chemotherapy conditioning, potentially increasing market size by four times according to management estimates. Conversely, negative clinical outcomes, regulatory setbacks, or competitive pressures from other gene editing companies could reduce the value of Beam's pipeline. The company also faces the inherent risks of biotechnology development, including the possibility that promising preclinical results may not translate to clinical success. Manufacturing costs for personalized cell therapies like BEAM-101 are typically high, which could impact future margins even if the treatments prove successful.
Competitive moat
Beam Therapeutics has built a potentially strong competitive moat through its proprietary base editing technology platform and extensive intellectual property portfolio. The company's base editing approach offers theoretical advantages over traditional gene editing methods like CRISPR-Cas9, as it can make precise single-letter DNA changes without creating double-strand breaks, potentially reducing unwanted side effects. The company's ESCAPE technology represents a particularly innovative moat, as it could fundamentally change the stem cell transplant paradigm by eliminating the need for chemotherapy conditioning. This breakthrough could provide Beam with a significant competitive advantage in treating genetic blood disorders, as current conditioning regimens are often too harsh for many patients, limiting the addressable market. However, the strength of this moat faces several challenges. The gene editing field is highly competitive, with well-funded companies like Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics developing competing approaches. Large pharmaceutical companies are also investing heavily in genetic medicine, and some may develop alternative solutions that could bypass Beam's technology entirely. The regulatory environment for gene editing remains evolving, and changes in approval pathways or safety requirements could impact Beam's competitive position. Additionally, the company's success depends heavily on clinical trial outcomes, and any significant safety issues or efficacy failures could quickly erode its technological advantages. The personalized nature of many of Beam's therapies also creates manufacturing complexity that could be challenging to scale economically.
Risks & safety
Beam Therapeutics presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong balance sheet metrics but significant operational risks. **Liquidity and Solvency:** - Strong cash position of $528 million as of Q1 2025, providing substantial runway - Excellent current ratio of 8.8x indicates strong short-term liquidity - Low debt-to-equity ratio of 0.14x suggests minimal financial leverage risk - Current cash burn rate of approximately $107 million per quarter (free cash flow) **Valuation Metrics:** - Trading at 1.5x price-to-book ratio, reasonable for a biotech company - Negative earnings and EBITDA make traditional valuation metrics less meaningful - Market cap of approximately $1.9 billion appears reasonable given pipeline potential **Other Considerations:** - High operational cash burn creates dependency on successful clinical outcomes or additional financing - Strong balance sheet provides time to execute on clinical programs - Revenue volatility due to partnership-dependent business model - Significant regulatory and clinical execution risks inherent in biotechnology sector
Recent development
Over the past few years, Beam Therapeutics has made significant strategic advances across its pipeline, with particular focus on advancing its lead sickle cell disease program and developing breakthrough conditioning technology. The company's BEAM-101 program for sickle cell disease has progressed into clinical trials, with initial data showing promising results including greater than 60% fetal hemoglobin induction and reduced sickle hemoglobin levels below 40%. A major strategic development has been the advancement of Beam's ESCAPE technology, which represents a potentially paradigm-shifting approach to stem cell transplantation. This technology combines a conditioning antibody (BEAM-103) with edited cell products to eliminate the need for chemotherapy conditioning, potentially expanding the addressable patient population by four times. The company has demonstrated proof-of-concept in non-human primate studies and plans to initiate human trials. The company has also expanded its liver disease portfolio with BEAM-302 for alpha-1 antitrypsin deficiency entering clinical trials, and BEAM-301 for glycogen storage disease receiving regulatory clearance. These programs diversify Beam's pipeline beyond blood disorders and target significant unmet medical needs in genetic liver diseases. Strategic partnerships have been a key component of Beam's development strategy, with collaborations established with major pharmaceutical companies including Pfizer and Apellis Pharmaceuticals. These partnerships provide validation of Beam's technology platform while generating revenue to fund internal programs.
BEAM company profile · for informational purposes only — not investment advice.
Track BEAM with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free